Credit Suisse’s Innate Pharma IPHA Stock Holding History

Credit Suisse’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,981	Closed	-$5K	–	4152
2022 Q2	$5K	Buy	+1,981	New	+$5.76K	﹤0.01%	3761

Other funds holding IPHA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Credit Suisse's IPHA Position: Q3 2022 in Review

Credit Suisse sold out of Innate Pharma (IPHA) in Q3 2022, closing a stake of 1,981 shares — an estimated $5K sold.

Credit Suisse first reported a position in IPHA in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 12 funds tracked by Wall St. Rank hold IPHA as of Q3 2022.

Credit Suisse reported no remaining Innate Pharma position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 1,981 Innate Pharma shares in Q3 2022, an estimated $5K.
Credit Suisse first reported a position in Innate Pharma in Q2 2022 and held it in 1 quarter.
Credit Suisse's Innate Pharma position peaked at $5K in Q2 2022.
12 funds tracked by Wall St. Rank held Innate Pharma as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.